📢 Gate Square #MBG Posting Challenge# is Live— Post for MBG Rewards!
Want a share of 1,000 MBG? Get involved now—show your insights and real participation to become an MBG promoter!
💰 20 top posts will each win 50 MBG!
How to Participate:
1️⃣ Research the MBG project
Share your in-depth views on MBG’s fundamentals, community governance, development goals, and tokenomics, etc.
2️⃣ Join and share your real experience
Take part in MBG activities (CandyDrop, Launchpool, or spot trading), and post your screenshots, earnings, or step-by-step tutorials. Content can include profits, beginner-friendl
Fudan Zhangjiang: The price reduction of Doxorubicin Liposome Injection is not less than 35%.
Jin10 News on April 30, Fudan Zhangjiang announced that the company has decided to adjust the market retail price of Doxorubicin Liposome Injection starting from May 1, 2025, with a price reduction of no less than 35% compared to the previous bidding price. The sales revenue of this drug in 2024 is expected to be approximately 210 million RMB, accounting for 29% of the company's total annual sales revenue. The price adjustment is expected to have an adverse impact on the company's sales revenue for 2025 and the subsequent execution period, potentially leading to a risk of single-product losses for this drug in 2025.